Abstract
The sustained-release of theophylline from several thermal modified starch matrices was evaluated in dogs in comparison to the commercial formulation Theodur 300. Matrices formulated with starches containing 70% amylose revealed a minor shift in t max in comparison with a conventional tablet. The matrices containing amylose free starches showed t max values of ±4 h. Starch matrices containing 25% amylose demonstrated a good sustained-release performance, comparable to Theodur 300. The influence of the drug/starch ratio was investigated on two types of starches containing 25% amylose: drum dried corn starch and extruded corn starch. A starch/drug ratio between 50 50 and 70 30 showed no significant influence on the biopharmaceutical parameters investigated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
